147 related articles for article (PubMed ID: 12651257)
1. Current use of imatinib in the treatment of chronic myeloid leukemia.
O'Dwyer M
Haematologica; 2003 Mar; 88(3):241-4. PubMed ID: 12651257
[No Abstract] [Full Text] [Related]
2. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
Smith BD
J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
[No Abstract] [Full Text] [Related]
3. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
[No Abstract] [Full Text] [Related]
4. Chronic myeloid leukemia in the imatinib era.
Druker BJ
Semin Hematol; 2003 Apr; 40(2 Suppl 2):1-3. PubMed ID: 12783367
[TBL] [Abstract][Full Text] [Related]
5. Trial results of a new combination therapy for myeloid leukaemia.
Leach S; Richardson C; Vowles JK; Charlton L
Nurs Times; 2002 Jul 16-22; 98(29):32-4. PubMed ID: 12168413
[TBL] [Abstract][Full Text] [Related]
6. Imatinib therapy in chronic myeloid leukemia.
Crossman LC; O'Brien SG
Hematol Oncol Clin North Am; 2004 Jun; 18(3):605-17, viii. PubMed ID: 15271395
[TBL] [Abstract][Full Text] [Related]
7. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
Wassmann B; Gökbuget N; Scheuring UJ; Binckebanck A; Reutzel R; Gschaidmeier H; Hoelzer D; Ottmann OG;
Ann Hematol; 2003 Nov; 82(11):716-20. PubMed ID: 14648032
[No Abstract] [Full Text] [Related]
8. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
9. Clinical results with imatinib in chronic myeloid leukaemia.
Crossman LC; O'Brien S
Leuk Res; 2004 May; 28 Suppl 1():S3-9. PubMed ID: 15036936
[TBL] [Abstract][Full Text] [Related]
10. Strategies for the treatment of imatinib-resistant chronic myeloid leukemia.
Hui CH; Hughes TP
Clin Adv Hematol Oncol; 2003 Sep; 1(9):538-45, 559. PubMed ID: 16258446
[TBL] [Abstract][Full Text] [Related]
11. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
Champlin RE; Kantarjian H
Clin Adv Hematol Oncol; 2003 Jul; 1(7):398-400. PubMed ID: 16258420
[No Abstract] [Full Text] [Related]
12. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF
Cancer; 2005 May; 103(9):1850-5. PubMed ID: 15786422
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
[No Abstract] [Full Text] [Related]
14. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
O'Brien SG; Deininger MW
Semin Hematol; 2003 Apr; 40(2 Suppl 2):26-30. PubMed ID: 12783372
[TBL] [Abstract][Full Text] [Related]
15. Imatinib results in better quality of life for CML patients than interferon/Ara-C.
J Support Oncol; 2003; 1(1):77. PubMed ID: 15352651
[No Abstract] [Full Text] [Related]
16. Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
Viniou NA; Vassilakopoulos TP; Giakoumi X; Mantzouranis M; Pangalis GA
Eur J Haematol; 2004 Jan; 72(1):58-60. PubMed ID: 14962264
[TBL] [Abstract][Full Text] [Related]
17. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
[TBL] [Abstract][Full Text] [Related]
18. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
19. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Singh T; Casson C
Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
[TBL] [Abstract][Full Text] [Related]
20. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
[No Abstract] [Full Text] [Related]
[Next] [New Search]